Good-Lite has stood as an industry cornerstone for over 90 years, earning its reputation as a leading developer and manufacturer of comprehensive visual acuity testing and screening solutions. Everything about our legacy—built on trust, expertise, and innovation—drives us to continually advance methodologies, technologies, and techniques. At the heart of our mission is the early detection of visual impairments, ensuring the highest standard of care for people at every stage of life.
Cyagen Biomodels LLC
Founded in 2006, Cyagen is a global provider of genetically modified rodent models and advanced CRO solutions for biomedical research and drug development. With more than 900 employees and research facilities covering 40,000 m², Cyagen supports researchers in over 100 countries and has contributed to more than 13,000 peer-reviewed publications, including in Cell, Nature, and Science. Headquartered in Santa Clara, California, Cyagen also operates subsidiaries in Japan and China, with major R&D and production centers in Guangzhou, Suzhou, and Gu’an. Combining expertise in cell and animal model generation with AI-driven discovery platforms, Cyagen provides scalable, reliable, one-stop solutions for basic research and preclinical drug development. Cyagen has developed several proprietary platforms to advance translational research, including HUGO-GT™ genomic humanized mouse models, the Rare Disease Data Center (RDDC) integrating genetic databases and AI tools
CMC Technical Solutions
CMC Consultants providing regulatory, quality assurance, quality control, project and program planning, internal/ external auditing, and operations support. We also offer creation and/ or review of SOPS, SDS, CPP, CoA, and Specifications. Offering QMS build, process/ project gap and risk assessment.
China Eye Valley
China Eye Valley is a national-level ophthalmic innovation ecosystem based in Wenzhou, China, integrating research, clinical care, industry, and investment. Anchored by the Wenzhou Medical University Eye Hospital, it supports the full pipeline from basic research to commercialization. The platform hosts over 400 eye health enterprises and offers advanced capabilities in biomaterials, medical devices, AI-driven diagnostics, and real-world evidence (RWE) studies. At ARVO, China Eye Valley showcases its collaborative model and seeks global partnerships to accelerate innovation, regulatory advancement, and market access in ophthalmology.
Celanese
Celanese’s VitalDose® drug delivery platform enables targeted ocular delivery of small molecules, biologics, and RNA for conditions like retinal disease, glaucoma, and inflammation. Offering both durable and degradable systems, the platform utilizes implants and inserts to ensure controlled drug release, reducing treatment burden while improving patient adherence and bioavailability. Partner with our Development & Feasibility Lab to overcome complex delivery challenges. Our experts are equipped to design and fabricate functional, drug-loaded prototypes, characterize morphology and release profiles, and provide seamless technical transfer support to meet your specific requirements. With decades of experience in medical and pharmaceutical applications, Celanese delivers world-class expertise and unrivaled service. We collaborate closely with you to refine development and elevate patient care through innovative, customized drug delivery solutions. | Celanese is a global leader in chemistry, producing specialty material solutions used across most major industries and consumer applications. Our businesses use our chemistry, technology and commercial expertise to create value for our customers, employees and shareholders. We are committed to sustainability by responsibly managing the materials we create for their entire lifecycle and are growing our portfolio of sustainable products to meet increasing customer and societal demand. We make a positive impact in our communities and prioritize diversity, equity and inclusion across our teams. Celanese is a Fortune 500 company that employs approximately 12,400 employees worldwide with 2023 net sales of $10.9 billion.
BioSpherix, LLC
BioSpherix stands at the forefront of advanced cell and tissue culture technology, dedicated to providing Cytocentric® environments designed for optimal cell care. Our flagship product, the Xvivo System, exemplifies this commitment. By harnessing our proprietary closed-system technology, the Xvivo System revolutionizes cell science and is expertly tailored to meet the demands of your GMP or R&D protocols. This modular and cost-effective system features patented self-sterilizing technology, offering a superior alternative to traditional open systems that expose cell and tissue cultures to unpredictable and non-physiologic conditions. The Xvivo System enhances operational efficiency, adapts to your evolving needs, minimizes contamination risks, and ultimately cultivates healthier, more robust cells. At BioSpherix, our philosophy is Cytocentric®: prioritizing the needs of cells above all else.
Aptar Pharma
Aptar Pharma is your go-to drug delivery partner, from formulation to patient. For pharmaceutical customers worldwide, Aptar Pharma provides innovative drug delivery systems, components & active material solutions across a wide range of delivery routes, including nasal, pulmonary, ophthalmic, dermal and injectables. Through Aptar Pharma Services, the company supports products from early development through commercialization, helping to accelerate and derisk the drug development journey. With a strong focus on innovation, Aptar Pharma is advancing digital health solutions designed to improve patient adherence and compliance. Aptar Pharma operates a global manufacturing network of approximately 15 sites, ensuring security of supply and strong local customer support worldwide. Aptar Pharma is part of AptarGroup, Inc.
Adaptive Sensory Technology
Adaptive Sensory Technology, Inc. (AST) is a leader in visual function endpoints and reading center services for the pharmaceutical industry. AST’s Manifold is an innovative data science platform that leverages an active learning architecture offering the first generative model for visual acuity and contrast sensitivity. The Manifold includes quantitative Contrast Sensitivity (qCSF), quantitative Visual Acuity (qVA), and multidimensional analyses of low-contrast and low-luminance vision. With a growing global network spanning over 200 retina sites, AST is advancing visual function endpoints that offer data-driven insights for ophthalmic clinical research. For more information, please contact us at info@adaptivesensorytech.com